Skip Navigation


Rheumatology Advance Access originally published online on July 9, 2009
Rheumatology 2009 48(10):1190-1196; doi:10.1093/rheumatology/kep199
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
48/10/1190    most recent
kep199v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Maillard-Lefebvre, H.
Right arrow Articles by Lambert, M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Maillard-Lefebvre, H.
Right arrow Articles by Lambert, M.
Related Collections
Right arrow Vasculitis
Right arrow Sjogren's Syndrome
Right arrow Rheumatoid Arthritis
Right arrow Systemic Lupus Erythematosus and Autoimmunity
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Reviews

Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and prognosis of chronic inflammatory diseases

Hélène Maillard-Lefebvre1,2, Eric Boulanger1,3, Maïté Daroux1, Cédric Gaxatte1,3, Barry I. Hudson4 and Marc Lambert1,2

1Department of Vascular Aging Biology, Medical School,2Department of Internal Medicine, Claude Huriez Hospital,3Department of Internal Medicine and Geriatrics, University Hospital of Lille, Lille, France and 4Department of Surgery, College of Physicians and Surgeons, Columbia University, New York, NY, USA.

Correspondence to: Hélène Maillard-Lefebvre, Department of Internal Medicine, Claude Huriez Hospital, University Hospital of Lille, 1 place de Verdun, 59037 Lille cedex, France. E-mail: helene.maillard{at}chru-lille.fr


  Abstract

The formation of advanced glycation end products (AGEs) is a result of the non-enzymatic reaction between sugars and free amino groups of proteins. AGEs, through interacting with their specific receptor for AGEs (RAGE), result in activation of pro-inflammatory states and are involved in numerous pathologic situations. The soluble form of RAGE (sRAGE) is able to act as a decoy to avoid interaction of RAGE with its pro-inflammatory ligands (AGEs, HMGB1, S100 proteins). sRAGE levels have been found to be decreased in chronic inflammatory diseases including atherosclerosis, diabetes, renal failure and the aging process. The use of measuring circulating sRAGEs may prove to be a valuable vascular biomarker and in this review, we describe the implications of sRAGE in inflammation and propose that this molecule may represent a future therapeutic target in chronic inflammatory diseases.

KEY WORDS: Advanced glycation end products, Receptor for advanced glycation end products, Soluble form of receptor for advanced glycation end products, Biomarker, Atherosclerosis, Inflammation, Chronic inflammatory diseases

Submitted 22 December 2008; revised version accepted 9 June 2009.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.